{
    "code": "02024662",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02024662",
    "time": "2023-06-08 20:58:30",
    "許可證字號": "衛署藥輸字第024662號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "117\/04\/01",
    "發證\/登錄日期": "96\/07\/11",
    "許可證\/登錄種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA00202466206",
    "中文品名": "喜必福 膜衣錠 600 毫克",
    "英文品名": "Sebivo 600mg film-coated tablets",
    "適應症": "用於具有病毒複製及活動性肝臟發炎證據的慢性B 型肝炎患者的治療。\r\n說明：\r\n對於HBeAg 陽性的患者，只有基礎值HBV DNA < 9 log10 copies\/ 毫升且基礎ALT ≥ 2×ULN 的患者，才可開始使用Sebivo 治療。\r\n對於HBeAg 陰性的患者，只有基礎值HBV DNA < 7 log10 copies\/ 毫升的患者，才可開始使用Sebivo 治療。\r\nTelbivudine 不建議用於對lamivudine 具抗藥性之患者；另有實驗證據顯示，本品亦不適用對entecavir具抗藥性的患者。\r\n本適應症是根據治療1 年以後B 型肝炎e 抗原（HBeAg） 呈陽性和陰性的成人慢性B 型肝炎患者在病毒學、血清學、生化學及組織學的反應結果。",
    "劑型": "116膜衣錠",
    "包裝": "2~1000粒鋁箔盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "TELBIVUDINE (LDT 600)",
    "限制項目": "02輸　入 1E須執行Phase IV Study 52依本署七七公告於國內進行臨床試驗且核定為新藥",
    "申請商名稱": "台灣邁蘭有限公司",
    "申請商地址": "臺北市信義區信義路５段7號27樓",
    "主製造廠": [
        {
            "製造廠名稱": "Mylan Laboratories Limited",
            "製造廠廠址": "F-4 &amp; F-12, MIDC, Malegaon, Sinnar, Nashik-442 113, Maharashtra, INDIA",
            "製造廠公司地址": "",
            "製造廠國別": "INDIA",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "Mylan Pharma GmbH",
            "製造廠廠址": "Turmstrasse 24 6312 Steinhausen, Switzerland",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": "許可證持有者"
        }
    ],
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "0818003300",
            "成分名稱": "TELBIVUDINE (LDT 600)",
            "含量描述": "",
            "含量": "600.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "20211202 GI_Sebivo-110-12-24.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024662&Seq=010&Type=8"
        },
        {
            "title": "20211202 FS_Sebivo-110-12-24.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024662&Seq=009&Type=8"
        }
    ]
}